ClinicalTrials.gg
CompletedNCT00618709Updated May 30, 2014

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

A Phase 1 interventional study of ATX-101 in Healthy, sponsored by Kythera Biopharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-30.

Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101

Read the detailed description

This is a single center, open-label, dose-escalation study in which subjects will receive 4 different dosage concentrations (3 dosing paradigms) of ATX-101 in a single dosing session.

02

Conditions studied

  • Healthy

Keywords

  • Healthy volunteers
03

In context

Lead sponsor

Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Kythera Biopharmaceuticals became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or nonpregnant females
  • Age 18 to 65
  • Sufficient submental fat for injections
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Prior interventions in the chin or neck area
  • History or presence of drug or alcohol abuse
  • Treatment with an agent within 30 days before the dose
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1

    ATX-101 (1 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid

    Drug: ATX-101

  • Experimental
    Cohort 2

    ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid

    Drug: ATX-101

  • Experimental
    Cohort 3

    3 subgroups in Cohort 3: 3a: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 3b: ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 3c: ATX-101 (2 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid

    Drug: ATX-101

  • Experimental
    Cohort 4

    3 subgroups in Cohort 4: 4a: ATX-101 (8 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 4b: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 4c: ATX-101 (4 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid

    Drug: ATX-101

Interventions

06

What researchers measure

Primary outcomes

  1. Safety assessed by: Laboratory tests

    Time frame: 12 weeks

  2. Safety assessed by: medical evaluations

    Time frame: 24 weeks

  3. Safety assessed by: ECG results

    Time frame: 24 weeks

Secondary outcomes

  1. Pharmacokinetic profile

    Cmax, tmax, AUC

    Time frame: 24 hours, before and after dosing

Other outcomes

  1. Pain assessed by visual analog scale

    Time frame: 24 weeks

07

Study locations

1 site
  • MDS Pharma Services
    Tempe, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2008
First posted
Feb 20, 2008
Start
Jan 2008
Primary completionActual
Dec 2008
CompletionActual
Jan 2009
Last update
May 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00618709
Responsible party
Sponsor
First posted
Feb 20, 2008
Start date
Jan 2008
Primary completion
Dec 2008
Completion
Jan 2009
Last update
May 30, 2014

Study contacts

Dennis Swearingin, M.D.
principal investigator · MDS Pharma Services
Frederick Beddingfield, M.D.
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APIM-containing Peptide ATX-101

Start the discussion